Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$32.74 - $68.76
Previous CloseN/A
Volume107.14K
Average Volume (3M)2.20M
Market Cap
$4.52B
Enterprise Value$5.27B
Total Cash (Recent Filing)$20.71M
Total Debt (Recent Filing)$724.00K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 01, 2025EPS Estimate
-1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.28
Shares Outstanding119,187,690
10 Day Avg. Volume2,685,264
30 Day Avg. Volume2,203,994
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)291.19
Price to Cash Flow (P/CF)-20.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit285.08
Enterprise Value/Ebitda-10.62
Forecast
1Y Price Target
$82.36Price Target Upside117.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Cytokinetics News
PremiumStock Analysis & Ideas
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
---
Bulls Say, Bears Say
Bulls Say
Market PotentialAficamten is projected to have a favorable commercial path forward and physician uptake as a potential best-in-class CMI for oHCM.
Product DifferentiationAficamten's efficacy and safety profile, along with its titration schedule, is viewed as potentially best-in-class for treating obstructive hypertrophic cardiomyopathy.
Regulatory EnvironmentRegulators appear increasingly comfortable with the treatment class, which should support broader category growth for aficamten.
Bears Say
Market CompetitionPotential headwinds challenging Bristol, given its 3-year first-to-market advantage and well-established sales footprint.
Payer ChallengesPayer pushback is likely to be significant regardless of the data, which is seen as the biggest barrier to 1L use.
Regulatory RestrictionsCamzyos label information still contains a Black Box Warning and is available only through a restricted REMS program.
---
Ownership Overview
0.80% Insiders
37.26% Mutual Funds
0.46% Other Institutional Investors
38.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $32.74 and its highest was $68.76 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $4.52B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is May 01, 2025 which is in 8 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Feb 27, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.193 by -$0.067.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.37.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 119,187,690 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.193. Following the earnings report the stock price went down -3.056%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
---
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.36 (117.83% Upside)
$82.36 (117.83% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 104.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.84%
12-Months-Change
Fundamentals
Return on Equity
435.49%
Trailing 12-Months
Asset Growth
70.04%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
---
CYTK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant regulatory progress and strategic partnerships for aficamten, a strong financial position, and pipeline advancements. However, increased expenses and ongoing regulatory challenges were noted. Despite these challenges, the progress and strategic moves position the company well for future growth.Read More>---
CYTK Stock 12 Month Forecast
Average Price Target
$82.36
▲(117.83% Upside)
Technical Analysis
Best Analysts Covering CYTK
1 Year
1 Year Success Rate
30/49 ratings generated profit
1 Year Average Return
+28.05%
reiterated a buy rating 2 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 61.22% of your transactions generating a profit, with an average return of +28.05% per trade.
---